NGM Biopharmaceuticals’ aldafermin failed to hit the primary endpoint in the company’s Phase IIb ALPINE 2/3 trial for non-alcoholic steatohepatitis (NASH) with stage 2 or 3 liver fibrosis.

Stephen Byers, Ph.D., associate director and professor of oncology at Georgetown Lombardi, and his team published a paper in the journal Gastroenterology regarding their findings of a novel target for pancreatic cancer therapy.

Inventiva, with headquarters in Daix, France, received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the company’s lanifibranor for nonalcoholic steatohepatitis (NASH).

Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Massachusetts-based Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis (CF).

Two years after nabbing three novel anti-infective drug candidates from Novartis for the treatment of antibiotic-resistant infections, Boston Pharmaceuticals struck a deal with the Swiss pharma giant for a potential treatment for non-alcoholic steatohepatitis (NASH).

Following negative interim data from the company’s experimental treatment for non-alcoholic steatohepatitis (NASH) and fibrosis, France’s GENFIT will discontinue the Phase III RESOLVE-IT study of elafibranor in this indication.

Lassen Therapeutics, based in San Diego, came out of stealth mode with a $31 million Series A financing round.

The U.S. Food and Drug Administration approved Boehringer Ingelheim’s Ofev (nintedanib) for patients with chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype.

As the J.P. Morgan Healthcare Conference continues to roll on with companies showcasing their pipelines and business plans, negative reports about the host city San Francisco have been made.

Researchers at the University of California-Los Angeles Health Sciences have developed a scar-in-a-dish model derived from stem cells that can mimic fibrosis.